v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

A DESCRIPTIVE STUDY ON THE FREQUENCY OF ANTI-TUBERCULOUS THERAPY INDUCED HEPATITIS

AUTHORS:

Muhammad Umair, Muhammad Faizan Akram, Muhammed Hamza Hassan Qadri

ABSTRACT:

Objective: The aim of this study was to determine the frequency of anti-tuberculous therapy (ATT) induced hepatitis. Methodology: This was a descriptive study and was carried out at Mayo Hospital Lahore from May 2020 to September 2020. In this study the cases of known Tuberculosis were included. Anti-Tuberculosis Therapy included Isoniazid, Rifampicin Ethambutol and Pyrazinamide according to standard WHO recommended doses. The cases suffering from hepatitis B, C or HIV or those with derange liver functions were excluded from this study. The cases were followed weekly and Liver function tests (LFTs) were performed and hepatitis was labelled as yes where there was rise in liver enzymes three times upper limit with symptoms (nausea/vomiting/abdominal pain) or 5 times without any symptoms. The final outcome was seen at 4 weeks. Results: In this study there were total 80 cases of TB out of which 60 (60%) were males and 20 (20%) females. The mean age of the subjects was 36.9± 9.43 years. There were 68 cases with pulmonary and 12 had EPTB. ATT induced hepatitis was observed in 4 (4%) of the cases. ATT induced hepatitis was significantly high in males affecting 3 (5.12%) cases with p value of 0.04. There was no significant difference in terms of weight groups with p= 0.68. Hepatotoxicity was more seen in cases having EPTB where 2 out of 12 cases had it; although this difference was statistically not significant with p=0.13. Conclusion: Anti-tuberculous therapy (ATT) induced hepatitis is uncommon but is seen significantly high in male gender. Keywords: Anti-Tuberculous Therapy, Hepatitis, Pyrazinamide, Hepatotoxicity, Rifampicin Ethambutol

FULL TEXT

<
Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.